RxDoctor Payments Data

Hazem Samir-Moez, MD

Internal Medicine · Hamtramck, MINPI 1992734214

Payments from drug & device makers

$1,443in general payments, 2019–2025

Across 85 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$240
  • AstraZeneca$212
  • Lilly USA, LLC$142
  • Bayer$101
  • AbbVie$100
  • Ironwood Pharmaceuticals, Inc$91
  • plus $556 from 14 others

What the payments were for

  • Food & beverage$1,443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,443 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$140,814
Medicare patients
211
Services billed
2,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate525$335,838
JardianceEmpagliflozin460$299,607
FarxigaDapagliflozin Propanediol409$260,237
LinzessLinaclotide238$144,552
JanumetSitagliptin Phos/Metformin Hcl189$115,786
TrulicityDulaglutide84$78,608
EliquisApixaban105$61,351
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$55,531
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog173$55,203
TradjentaLinagliptin71$47,632
OzempicSemaglutide38$34,944
XareltoRivaroxaban54$25,683
Breo ElliptaFluticasone/Vilanterol62$25,044
VascepaIcosapent Ethyl121$24,474
EntrestoSacubitril/Valsartan34$21,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr, Verquvo$87$474,678754 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Synjardy Xr$83$365,604558 claims
AstraZenecaFarxiga, Symbicort$212$269,792452 claims
AbbVieLinzess, Creon, Restasis$100$166,839277 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$40$88,822166 claims
Lilly USA, LLCTrulicity$142$78,60884 claims
PfizerEliquis$240$61,351105 claims
Novo NordiskOzempic, Rybelsus$11$55,35055 claims
NovartisEntresto$41$21,38734 claims
BayerKerendia$101$20,09933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Hamtramck

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →